3 top stock recommendations from Sarita Pansari
My first pick will be Hikal which is currently trading at Rs 307 and targets for Hikal will be Rs 329-335 with stop loss of Rs 300.06-03-2023
06-03-2023
HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Submission of transcript of Earnings call for quarter and period ended December 31, 2022 under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 201508-02-2023
Hold Hikal; target of Rs 375: ICICI Direct
ICICI Direct recommended hold rating on Hikal with a target price of Rs 375 in its research report dated February 03, 2023.07-02-2023
HIKAL LTD. - 524735 - Announcement Under Regulation 30 Of The SEBI Listing Regulations
Intimation under Regulation 30 of the SEBI Listing Regulations - Communication to Shareholders regarding withholding tax on Dividend07-02-2023
HIKAL LTD. - 524735 - Intimation Under Regulation 30 Of SEBI (LODR) - Earnings Call Audio Recording Q3 FY23
Intimation Under Regulation 30 Of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Earnings Call Audio Recording Q3 FY2302-02-2023
HIKAL LTD. - 524735 - Corporate Action-Board approves Dividend
The Board of Directors of the Company at its meeting held today i.e., February 2, 2023 declared an Interim Dividend on the Equity Shares of the Company for the financial year 2022-23.02-02-2023
HIKAL LTD. - 524735 - Corporate Action - Fixes Record Date For Interim Dividend For Financial Year 2022-23
Intimation of Record date for the purpose of payment of interim dividend for the financial year 2022-2302-02-2023
Q3FY23 Quarterly Result Announced for Hikal Ltd.
Pharmaceuticals firm Hikal announced Q3FY23 results: Q3FY23: Revenue of Rs 540 crore YoY growth of 5% EBITDA of Rs 75 crore QoQ growth of 7% PAT stood at Rs 26 crore. Hikal’s long-term credit rating is maintained at A+ by ICRA. Interim Dividend of Rs 0.60 per share (30% of Face Value). Commenting on the results, Jai Hiremath, Executive Chairman, of Hikal Ltd. said, “Hikal has recorded an improved performance in this quarter in line with earlier guidance of a sequential recovery. We had an improvement in EBITDA margins on the back of several cost-improvement initiatives. We are witnessing softening of key raw material prices and we expect the trend to stabilize in the upcoming quarter. The revenue for the Crop Protection business stood at Rs 248 crore in Q3FY22. We are focusing on the optimal product mix to improve revenues and margins going forward. We are in the process of commissioning our new multipurpose facility at Panoli for the launch of our new products. Our Pharmaceuticals business has registered a YoY revenue growth of 9% and revenue stood at Rs 292 crore for the quarter based on increased volumes of CDMO products. We have a strong pipeline of products in various stages of development. We are focusing on cost-improvement initiatives to improve margins for existing APIs and improve penetration of new products across different geographies. Our new Animal Health Multipurpose facility is on track and expected to be commissioned in Q2FY24. The board has approved an interim dividend of Rs 0.60 per share which translates to 30% of the Face Value. Hikal has partnered with a leading global ESG consultant to build the sustainability strategy for the reduction of carbon footprint across the value chain of Hikal to better understand the needs of all our stakeholders, colleagues, partners and communities in which we operate. As part of our commitment to doing business in a responsible way, we are taking several initiatives to ensure clean energy, reduction of carbon footprint, and reduction of waste generation across all our sites. We have further increased renewable power by signing long-term agreements for our Panoli, Taloja and Mahad sites. Pinnacle, our business transformation initiative, is on track to create a robust roadmap across business verticals to drive profitable and sustainable growth over the next five years through a focused strategic direction. We continue to monitor the macro-economic environment, rising interest rates, the impact of China opening, rising energy costs and the ongoing geopolitical unrest. Both of our businesses have a strong growth outlook. We aspire to deliver sustainable and profitable volume-led growth over the medium term.” Result PDF02-02-2023
HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation of the Company for the quarter and period ended December 31, 202202-02-2023